(177)Lu-PSMA-617 radioligand therapy for a patient with lymph node metastatic prostate cancer

Prostate specific membrane antigen (PSMA) is expressed in unfavorable prostate cancer. PSMA is basis for new diagnostics and theranostics. PET/CT using PSMA is more sensitive than choline PET/CT. (177)Lu-PSMA radioligand therapy is mainly used for patients with end-stage prostate cancer. This report...

Descripción completa

Detalles Bibliográficos
Autores principales: von Eyben, Finn E., Kiljunen, Timo, Joensuu, Timo, Kairemo, Kalevi, Uprimny, Christian, Virgolini, Irene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630396/
https://www.ncbi.nlm.nih.gov/pubmed/29029496
http://dx.doi.org/10.18632/oncotarget.19805

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630396/
https://www.ncbi.nlm.nih.gov/pubmed/29029496
http://dx.doi.org/10.18632/oncotarget.19805

Ejemplares similares